Andrea B. Parker
Corporate Officer/Principal presso CARDIOL THERAPEUTICS INC.
Profilo
Andrea B.
Parker is currently the Senior Director-Clinical Operations at Cardiol Therapeutics, Inc. Her former jobs include being the Director-Clinical Affairs at Vasogen, Inc. from 2003 to 2006, Managing Director-North American Office at SOCAR Research SA from 1989 to 2001, Managing Director at a Contract Research Organization, Vice President-Clinical Development at CNP Therapeutics, Inc., and Chief Scientific Officer at Toronto General Hospital and Peter Munk Cardiac Centre from 2010 to 2019.
Dr. Parker has a doctorate from the University of Toronto, a graduate degree from Universität Leipzig, and a graduate degree from Harvard T.H.
Chan School of Public Health.
Posizioni attive di Andrea B. Parker
Società | Posizione | Inizio |
---|---|---|
CARDIOL THERAPEUTICS INC. | Corporate Officer/Principal | 01/07/2019 |
Precedenti posizioni note di Andrea B. Parker
Società | Posizione | Fine |
---|---|---|
Toronto General Hospital
Toronto General Hospital Hospital/Nursing ManagementHealth Services Toronto General Hospital provides health care service. Its programs include medical and community care, multi-organ transplant, peter munk cardiac centre, surgery and critical care. The company was founded in and is headquartered in Toronto, Canada. | Corporate Officer/Principal | 01/01/2019 |
Peter Munk Cardiac Centre | Chief Tech/Sci/R&D Officer | 01/01/2019 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Chief Tech/Sci/R&D Officer | 01/01/2006 |
SOCAR Research SA
SOCAR Research SA BiotechnologyHealth Technology SOCAR Research SA provides clinical research services. It provides services in the areas which include cardiovascular and related, cachexia, hematology, hypertension, metabolic, nephrology, nutraceuticals and oncology telemedicine. The firm's technology include e-SOCDAT is an e-clinical solution which provides e-design, e-data and e-data services. It serves the biotechnology, consumer healthcare, medical device, pharmaceutical, contract research organization and academic institutions. The company was founded in 1986 and is headquartered in Nyon, Switzerland. | Corporate Officer/Principal | 01/01/2001 |
Contract Research Organization | Corporate Officer/Principal | - |
Formazione di Andrea B. Parker
University of Toronto | Doctorate Degree |
Universität Leipzig | Graduate Degree |
Harvard T.H. Chan School of Public Health | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Aziende private | 6 |
---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
CNP Therapeutics, Inc.
CNP Therapeutics, Inc. Medical SpecialtiesHealth Technology CNP Therapeutics, Inc. manufactures medical systems for chronic pain, depression and anxiety. The company was founded by Frank Prato and Alex Thomas on September 16, 1998 and is headquartered in Mississauga, Canada. | Health Technology |
SOCAR Research SA
SOCAR Research SA BiotechnologyHealth Technology SOCAR Research SA provides clinical research services. It provides services in the areas which include cardiovascular and related, cachexia, hematology, hypertension, metabolic, nephrology, nutraceuticals and oncology telemedicine. The firm's technology include e-SOCDAT is an e-clinical solution which provides e-design, e-data and e-data services. It serves the biotechnology, consumer healthcare, medical device, pharmaceutical, contract research organization and academic institutions. The company was founded in 1986 and is headquartered in Nyon, Switzerland. | Health Technology |
Toronto General Hospital
Toronto General Hospital Hospital/Nursing ManagementHealth Services Toronto General Hospital provides health care service. Its programs include medical and community care, multi-organ transplant, peter munk cardiac centre, surgery and critical care. The company was founded in and is headquartered in Toronto, Canada. | Health Services |
Contract Research Organization | |
Peter Munk Cardiac Centre |
- Borsa valori
- Insiders
- Andrea B. Parker